# Regioselective Synthesis of Poly-Substituted Pyrroles from Baylis-Hillman Adducts *via* the [3+1+N] Annulation Strategy

## Jeong Mi Kim, Sangku Lee,<sup>†</sup> Se Hee Kim, Hyun Seung Lee, and Jae Nyoung Kim<sup>\*</sup>

Department of Chemistry and Institute of Basic Science, Chonnam National University, Gwangju 500-757, Korea \*E-mail: kimjn@chonnam.ac.kr \*Natural Medicine Research Center, KRIBB, Daejeon 305-806, Korea Received August 19, 2008

Poly-substituted pyrrole derivatives were synthesized from Baylis-Hillman adducts *via* the following consecutive reactions comprised of (i) bromination of the Baylis-Hillman adduct, (ii) In-mediated Barbier reaction with aldehyde, (iii) PCC oxidation to  $\alpha$ -methylene- $\gamma$ -keto ester, (iv) reaction with amine to form enamine intermediate, (v) Michael type cyclization, and the final (vi) aerobic oxidation.

Key Words : Pyrroles, Baylis-Hillman adducts, Barbier reaction, PCC, Aerobic oxidation

### Introduction

Suitably substituted pyrroles are the basic skeleton of many biologically important substances<sup>1,2</sup> and numerous methods for the synthesis of pyrrole derivatives have been investigated extensively.<sup>1,2</sup> The synthetic applicability of Baylis-Hillman adducts has also been reported in many papers.<sup>3-5</sup> However, the synthesis of pyrrole derivatives from Baylis-Hillman adducts has not been reported much.<sup>4,5</sup> Very recently, we reported the synthesis of 2,3,4-trisubstituted pyrroles starting from the rearranged *aza*-Baylis-Hillman

adducts involving [3+N+1] annulation.<sup>5a</sup> We also developed another efficient synthetic method of poly-substituted pyrroles by using [3+(N+1)] annulation.<sup>5b</sup>

## **Results and Discussion**

During the studies we imagined that we could synthesize 2,3,4-trisubstituted pyrroles by following the reaction sequence shown in Scheme 1 *via* the [3+1+N] *annulation* strategy. At the earliest stage of this project our synthetic rationale was the first construction of dihydropyrrole skele-



•						
Entry	2+3	Compound 4 (%) <sup><math>a</math></sup>	Compound <b>5</b> $(\%)^b$	Compound 6	Product <b>9</b> (%) <sup><i>c</i></sup>	Product <b>10</b> (%) <sup>c</sup>
1	2a+3a	<b>4a</b> (93)	<b>5a</b> (90)	6a	<b>9a</b> (50)	<b>10a</b> (5)
2				6b	<b>9b</b> (46)	<b>10b</b> (9)
3				6c	<b>9c</b> (47)	<b>10c</b> (2)
4	2b+3a	<b>4b</b> (91)	<b>5b</b> (88)	6a	<b>9d</b> (45)	<b>10a</b> (6)
5				6b	<b>9e</b> (40)	<b>10b</b> (11)
6	2c+3a	<b>4c</b> (83)	<b>5c</b> (85)	6a	<b>9f</b> (45)	<b>10f</b> (trace) <sup><math>d</math></sup>
7	2b+3b	<b>4d</b> (60)	<b>5d</b> (68)	6a	<b>9g</b> (40)	<b>10g</b> (trace) <sup><math>d</math></sup>

 Table 1. Synthesis of poly-substituted pyrroles

<sup>*a*</sup>Compound **2** (2.0 mmol), aldehyde **3** (1.5 equiv), In (1.1 equiv), aq THF, rt, 1-2 h. <sup>*b*</sup>Compound **4** (1.0 mmol), PCC (2.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, rt, 4 h. <sup>*c*</sup>Compound **5** (0.5 mmol), amine **6** (1.5 equiv), AcOH (1.0 equiv), toluene, 80-90 °C, 5-7 h. <sup>*d*</sup>Not isolated.

ton 8 and the second oxidation process to pyrrole 9.

Thus we prepared starting material 5a from Baylis-Hillman adduct 1a according to the reported method: (i) bromination of Baylis-Hillman adduct 1a to cinnamyl bromide 2a (95%, HBr),<sup>3,6</sup> (ii) In-mediated Barbier reaction of 2a and benzaldehyde (3a) to make 4a (93%),<sup>6</sup> (iii) PCC oxidation of 4a to  $\alpha$ -methylene- $\gamma$ -keto ester 5a (90%). With this compound 5a in our hand, we examined the reaction of 5a and benzylamine (6a) under various conditions. Among the examined conditions the use of AcOH (1.0 equiv) in toluene was the best choice. Under the conditions we obtained 9a (50%) and the corresponding amide derivative 10a (5%). During the reaction progress we observed the presence of a small amount of dihydropyrrole intermediate 8a which converted into the pyrrole 9a (vide infra). We tried the synthesis of dihydropyrrole 8a. When the reaction of 5a and 6a was carried out under strictly controlled nitrogen atmosphere (0.1 equiv of CF<sub>3</sub>COOH, benzene, reflux, 24 h), we observed the formation of 8a in appreciable amounts together with 9a (14%) and remaining 5a (32%). Compound

**8a** was isolated in 35% yield by rapid column chromatography and identified the structure by <sup>1</sup>H and <sup>13</sup>C NMR spectra as correct.<sup>7</sup> However, this compound **8a** was oxidized rapidly, and converted to **9a** spontaneously. The conversion of **8a** into **9a** can be explained by aerobic oxidation.<sup>8</sup> Encouraged by the results we made other  $\alpha$ -methylene- $\gamma$ keto esters **5b-d** and examined the reactions with some representative amines, benzylamine (**6a**), phenethyl amine (**6b**), and *sec*-phenethylamine (**6c**). The results are summarized in Table 1.

As shown in Table 1, we made 2,3,4-trisubstituted pyrroles **9a-g** in moderate yields (40-50%) and we observed some amide derivatives **10a-g** (trace-11%), which was isolated in most cases. The reaction mechanism for the formation of dihydropyrrole intermediate could be explained as in Scheme 1 involving the formation of enamine intermediate 7 and the following Michael type cyclization to **8**.<sup>9,10</sup> However, the mechanism involving the initial formation of Michael addition product 7' and the following dehydrative cyclization to **8** cannot be excluded.



Scheme 2

Regioselective Synthesis of Poly-Substituted Pyrroles

 Table 2. Reaction of 5a and anilines 11



 6
 11a (2.0 equiv) CF<sub>3</sub>COOH (1.0 equiv), 48 h
 17a/18a (7/7<sup>d</sup>)

 7
 11b (3.0 equiv) AcOH (2.0 equiv), 24 h
 17b/18b (50/14)

 8
 11c (3.0 equiv) AcOH (2.0 equiv), 48 h
 17c/18c (37/11<sup>e</sup>)

<sup>*a*</sup>Toluene was used as solvent, 80-90 °C. <sup>*b*</sup>Isolated yield of pure product. <sup>*c*</sup>Starting material **5a** was recovered in 23% yield. <sup>*d*</sup>Starting material **5a** was recovered in 21% and trifluoroacetamide derivative of **11a** was isolated in 10%. <sup>*c*</sup>In compound **18c** small amount of **17c** was contaminated.

As a next trial, we examined the reaction of 5a and aniline (11c) under the same conditions (1.0 equiv of AcOH in toluene). However, the reaction was sluggish and many compounds were observed on TLC (vide infra). Thus, we examined the reaction with electron-rich 2,4-dimethoxyaniline (11a). When we used 1.0 equiv of AcOH we isolated compound 17a in only 14% yield (entry 2 in Table 2). From the reaction compound 18a was isolated as the major product (39%) interestingly. The formation of 17a and 18a can be explained as in Scheme 2. Compound 17a can be produced as for the compounds 9a-g involving the intermediate enamine 12a and dihydropyrrole 15a. Whereas, compound 18a might be formed via the sequential process: (i) Michael addition of 11a to 12a to form 13a, (ii) aerobic oxidation to 14a,<sup>11</sup> (iii) acid-catalyzed cyclization of 14a to 16a and the final (iv) aerobic oxidation.<sup>8</sup> In these respects, the yield and the ratio between 17a/18a could be changed by modification of reaction conditions. Thus we examined the reaction of 5a and 11a in six different conditions (entries 1-6 in Table 2). Although combined yield of 17a and 18a was not changed much, the ratio between 17a/18a was influenced by the amount of acetic acid, dramatically. Compound 17a was obtained as the major (58%) with 6.0 equiv of AcOH (entry 4), whereas compound 18a was the major (52%) with 0.5 equiv of AcOH (entry 1). The effect of AcOH on the ratio of 17a/18a is not clear at this stage. The use of formic acid and CF<sub>3</sub>COOH showed low yields of products (entries 5 and 6). The reaction with 4-methoxyaniline (11b) afforded 17b (50%) and 18b (14%) as in entry 7, similarly. The reaction with aniline (11c, vide supra) showed sluggish reactivity, however we obtained the corresponding pyrroles 17c and 18c after 48 h, albeit in low yields (entry 8).

In summary, we disclosed an efficient synthetic method of

poly-substituted pyrroles starting from the Baylis-Hillman adducts *via* the [3+1+N] *annulation* protocol. Further synthetic applications of this methodology are under progress actively in our group.

#### **Experimental Section**

**General procedure.** <sup>1</sup>H NMR (300 MHz) and <sup>13</sup>C NMR (75 MHz) spectra were recorded in CDCl<sub>3</sub>. The signal positions are reported in ppm relative to TMS ( $\delta$  scale) used as an internal standard. IR spectra are reported in cm<sup>-1</sup>. Mass spectra were obtained from the Korea Basic Science Institute (Gwangju branch). The elemental analyses were carried out at Korea Research Institute of Chemical Technology, Taejon, Korea. All reagents were purchased from commercial sources and used without further treatment. The separations were carried out by flash column chromatography over silica gel (230-400 mesh ASTM). Organic extracts were dried over anhydrous MgSO<sub>4</sub> and the solvents were evaporated on a rotary evaporator under water aspirator pressure.

Typical procedure for the synthesis of starting material 4a. A mixture of cinnamyl bromide 2a (538 mg, 2.0 mmol), benzaldehyde (3a, 318 mg, 3.0 mmol), and indium powder (253 mg, 2.2 mmol) in aqueous THF (1:1, 5 mL) was stirred at room temperature for 2 h. After the usual aqueous workup and column chromatographic purification (hexanes/EtOAc, 10:1) process, desired compound 4a (551 mg, 93%) was obtained as colorless oil. Syntheses of compounds 4b-d were carried out similarly and the representative spectroscopic data are as follows.

Compound **4a**: 93%; colorless oil; IR (film) 3498, 3030, 1714, 1144 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  1.13 (t, J = 7.2 Hz, 3H), 2.11 (br s, 1H), 3.94-4.05 (m, 2H), 4.30 (d, J = 7.8 Hz, 1H), 5.26 (d, J = 7.8 Hz, 1H), 5.78 (s, 1H), 6.23 (s, 1H), 7.20-7.33 (m, 10H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  13.92, 54.23, 60.73, 75.67, 126.53, 126.94, 127.10, 127.69, 128.16, 128.43, 129.18, 138.68, 141.29, 142.04, 166.45.

Compound **4b**: 91%; colorless oil; IR (film) 3503, 3030, 1717, 1144 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  2.30 (d, J = 3.6 Hz, 1H), 3.48 (s, 3H), 4.26 (d, J = 7.8 Hz, 1H), 5.16-5.20 (m, 1H), 5.74 (s, 1H), 6.18 (s, 1H), 7.16-7.30 (m, 10H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  51.63, 54.03, 75.41, 126.69, 126.80, 126.90, 127.48, 127.69, 128.23, 129.06, 138.56, 140.93, 142.03, 166.78.

Compound **4c**: 83%; colorless oil; IR (film) 3461, 2931, 1713, 1151 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  0.82 (t, *J* = 6.6 Hz, 3H), 1.05-1.26 (m, 6H), 1.29 (t, *J* = 7.2 Hz, 3H), 1.50-1.66 (m, 2H), 2.83 (d, *J* = 3.0 Hz, 1H), 2.92-2.99 (m, 1H), 4.19 (q, *J* = 7.2 Hz, 2H), 4.84 (dd, *J* = 5.1 Hz and 3.0 Hz, 1H), 5.42 (s, 1H), 6.22 (s, 1H), 7.19-7.33 (m, 5H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  13.97, 14.12, 22.45, 27.03, 27.34, 31.75, 49.37, 60.94, 76.44, 126.47, 126.76, 127.15, 127.91, 140.89, 142.65, 168.03.

Compound **4d**: 60%; colorless oil; IR (film) 3528, 2953, 1721, 1146 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  0.88 (t, J = 7.5 Hz, 3H), 1.24-1.32 (m, 4H), 1.36-1.39 (m, 2H), 1.44-1.56 (m, 3H), 3.68 (s, 3H), 3.91 (d, J = 6.5 Hz, 1H), 4.13-

4.14 (m, 1H), 5.88 (s, 1H), 6.36 (s, 1H), 7.22-7.26 (m, 1H), 7.29-7.33 (m, 4H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  13.99, 22.58, 25.57, 31.71, 35.35, 51.94, 52.46, 72.74, 126.04, 127.03, 128.50, 129.27, 138.86, 141.71, 167.25.

Typical procedure for the synthesis of compound 5a. A mixture of 4a (296 mg, 1.0 mmol) and PCC (430 mg, 2.0 mmol) in  $CH_2Cl_2$  (4 mL) was stirred at room temperature for 4 h. The reaction mixture was diluted with  $CH_2Cl_2$  and filtered through a pad of Celite. After removal of solvent under reduced pressure and column chromatographic purification (hexanes/EtOAc, 15:1) process, desired 5a (265 mg, 90%) was obtained as a white solid. Syntheses of compounds 5b-d were carried out similarly and the representative spectroscopic data are as follows.

Compound **5a**: 90%; white solid, mp 51-53 °C; IR (film) 2981, 1713, 1684, 1137 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  1.19 (t, J = 7.2 Hz, 3H), 4.12-4.22 (m, 2H), 5.26 (s, 1H), 5.89 (s, 1H), 6.48 (s, 1H), 7.21-7.38 (m, 7H), 7.42-7.48 (m, 7H), 7.96-8.00 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  13.88, 55.21, 60.96, 127.54, 128.22, 128.37, 128.70, 128.95, 129.42, 132.78, 135.50, 136.22, 140.48, 166.34, 197.36.

Compound **5b**: 88%; white solid, mp 73-75 °C; IR (film) 2951, 1716, 1682, 1139 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  3.74 (s, 3H), 5.28 (s, 1H), 5.88 (s, 1H), 6.47 (s, 1H), 7.24-7.40 (m, 7H), 7.45-7.50 (m, 1H), 7.95-7.98 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  52.15, 55.32, 127.66, 128.50, 128.65, 128.84, 129.06, 129.52, 132.91, 135.60, 136.27, 140.16, 167.01, 197.42.

Compound **5c**: 85%; colorless oil; IR (film) 2957, 2931, 1713, 1687, 1221 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  0.83-0.88 (m, 3H), 1.25-1.33 (m, 9H), 1.64-1.71 (m, 1H), 1.92-2.00 (m, 1H), 4.19-4.26 (m, 2H), 4.68 (t, *J* = 7.2 Hz, 1H), 5.71 (s, 1H), 6.36 (s, 1H), 7.41-7.47 (m, 2H), 7.51-7.56 (m, 1H), 7.99-8.03 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  13.89, 14.02, 22.34, 27.26, 31.72, 32.46, 46.83, 61.13, 126.71, 128.50 (2C), 132.88, 136.63, 139.29, 166.49, 199.97.

Compound **5d**: 68%; colorless oil; IR (film) 2954, 2931, 1716, 1633, 1140 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  0.83 (t, *J* = 7.2 Hz, 3H), 1.14-1.28 (m, 4H), 1.49-1.60 (m, 2H), 2.39-2.63 (m, 2H), 3.76 (s, 3H), 4.98 (s, 1H), 5.24 (s, 1H), 6.38 (s, 1H), 7.16-7.20 (m, 2H), 7.27-7.39 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  13.79, 22.28, 23.38, 31.07, 42.27, 52.04, 59.73, 127.71, 128.00, 128.94, 129.58, 135.05, 139.61, 167.10, 207.85.

**Typical procedure for the synthesis of compounds 9a and 10a.** A mixture of g-keto ester **5a** (147 mg, 0.5 mmol) and benzylamine (**6a**, 81 mg, 0.75 mmol) in AcOH (30 mg, 0.5 mmol) and toluene (0.5 mL) was heated to 80-90 °C for 5 h. After removal of solvent under reduced pressure and column chromatographic purification (hexanes/EtOAc, 4:1) process, desired pyrrole **9a** (96 mg, 50%) and amide compound **10a** (11 mg, 5%) was obtained. The other entries were carried out similarly and the spectroscopic data of **9a-g** and **10a-c** are as follows.

Compound **9a**: 50%; yellow solid, mp 116-117 °C; IR (film) 2979, 1713, 1520, 1240 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  1.15 (t, J = 7.2 Hz, 3H), 4.15 (q, J = 7.2 Hz, 2H),

5.00 (s, 2H), 6.99-7.29 (m, 15H), 7.46 (s, 1H);  $^{13}$ C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  14.16, 51.19, 59.40, 114.15, 124.50, 125.95, 126.91, 127.05, 127.38, 127.70, 127.73, 128.11, 128.70, 130.87, 131.14, 131.18, 133.33, 134.63, 137.17, 164.61; ESIMS *m*/*z* 382 (M<sup>+</sup>+1). Anal. Calcd for C<sub>26</sub>H<sub>23</sub>NO<sub>2</sub>: C, 86.86; H, 6.08; N, 3.67. Found: C, 86.99; H, 6.43; N, 3.31.

Compound **10a**: 5%; yellow gum; IR (film) 3419, 3062, 1647, 1534 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  4.38 (d, J = 5.7 Hz, 2H), 5.00 (s, 2H), 5.67 (t, J = 5.7 Hz, 1H), 7.00-7.35 (m, 20H), 7.50 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  43.28, 51.27, 118.12, 121.31, 126.16, 126.98, 127.02, 127.11, 127.43, 127.70, 127.72, 128.09, 128.36 (2C), 128.70, 130.98, 131.00, 131.12, 132.91, 134.58, 137.20, 138.30, 164.62; ESIMS *m/z* 443 (M<sup>+</sup>+1).

Compound **9b**: 46%; yellow solid, mp 78-80 °C; IR (film) 2979, 1713, 1521, 1120 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  1.17 (t, J = 7.2 Hz, 3H), 2.86 (t, J = 7.8 Hz, 2H), 4.01 (t, J = 7.8 Hz, 2H), 4.16 (q, J = 7.2 Hz, 2H), 6.89-6.92 (m, 2H), 6.99-7.05 (m, 2H), 7.10-7.27 (m, 1H), 7.45 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  14.19, 37.72, 49.14, 59.34, 113.70, 124.43, 125.90, 126.73, 127.03, 127.70, 128.17 (2C), 128.57, 128.58, 130.85, 131.05, 131.35, 132.88, 134.69, 137.54, 164.64; LCMS m/z 396 (M<sup>+</sup>+1).

Compound **10b**: 9%; yellow solid; IR (film) 3421, 2927, 1643, 1535 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  2.62 (t, J = 7.2 Hz, 2H), 2.88 (t, J = 7.8 Hz, 2H), 3.43-3.50 (m, 2H), 4.01 (t, J = 7.8 Hz, 2H), 5.40 (t, J = 5.7 Hz, 1H), 6.89-6.99 (m, 6H), 7.06-7.25 (m, 14H), 7.50 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  35.31, 37.80, 40.38, 49.02, 117.85, 120.97, 125.20, 126.13, 126.69, 126.92, 127.61, 128.08, 128.24, 128.41, 128.54, 128.55, 128.61, 130.84, 130.87, 131.22, 132.54, 134.58, 137.66, 139.03, 164.77; LCMS *m/z* 471 (M<sup>+</sup>+1).

Compound **9c**: 47%; yellow solid, mp 97-99 °C; IR (film) 2980, 1714, 1519, 1214 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  1.16 (t, J = 7.2 Hz, 3H), 1.79 (d, J = 7.2 Hz, 3H), 4.16 (q, J = 7.2 Hz, 2H), 5.26 (q, J = 7.2 Hz, 1H), 7.00-7.29 (m, 15H), 7.58 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  14.18, 22.20, 55.37, 59.43, 114.05, 124.12, 124.31, 125.86, 125.90, 126.99, 127.49, 127.78, 128.05, 128.63, 130.86, 131.38, 131.42, 133.47, 134.69, 142.27, 164.83.

Compound **10c**: 2%; yellow solid; IR (film) 3413, 3061, 1683, 1532 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  1.21 (d, *J* = 6.6 Hz, 3H), 1.77 (d, *J* = 6.9 Hz, 3H), 5.04-5.16 (m, 1H), 5.23 (q, *J* = 6.9 Hz, 1H), 5.64 (d, *J* = 8.4 Hz, 1H), 6.95-7.28 (m, 20H), 7.63 (s, 1H).

Compound **9d**: 45%; white solid, mp 127-129 °C; IR (film) 3029, 1716, 1520, 1122 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  3.68 (s, 3H), 5.01 (s, 2H), 7.00-7.34 (m, 15H), 7.45 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  50.74, 51.23, 113.64, 124.56, 126.03, 126.98, 127.14, 127.46, 127.75, 127.79, 128.15, 128.74, 130.81, 131.14, 131.17, 133.44, 134.47, 137.09, 164.94.

Compound **9e**: 40%; yellow solid, mp 106-107 °C; IR (film) 2946, 1716, 1223, 1122 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  2.86 (t, *J* = 7.8 Hz, 2H), 3.69 (s, 3H), 4.03 (t, *J* = 7.8 Hz, 2H), 6.89-6.92 (m, 2H), 7.00-7.03 (m, 2H), 7.13-7.27

(m, 11H), 7.44 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) *δ* 37.71, 49.17, 50.74, 113.21, 124.49, 125.98, 126.76, 126.82, 127.11, 127.75, 128.20, 128.59 (2C), 130.80, 131.07, 131.31, 132.99, 134.54, 137.51, 165.00.

Compound **9f**: 45%; yellow oil; IR (film) 2954, 2929, 1705, 1237 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  0.80 (t, J = 6.6 Hz, 3H), 1.17-1.28 (m, 4H), 1.33 (t, J = 7.2 Hz, 3H), 1.45-1.55 (m, 2H), 2.54-2.59 (m. 2H), 4.27 (q, J = 7.2 Hz, 2H), 4.89 (s, 2H), 6.89-6.92 (m, 2H), 7.14-7.38 (m, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  14.02, 14.47, 22.39, 25.28, 31.41, 31.87, 51.08, 59.25, 113.75, 124.45, 126.82, 127.05, 127.52, 127.88, 128.24, 128.58, 130.99, 131.65, 132.79, 137.48, 165.17; LCMS *m/z* 376 (M<sup>+</sup>+1).

Compound **9g**: 40%; yellow oil; IR (film) 2957, 2929, 1713, 1176 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  0.75 (t, *J* = 6.6 Hz, 3H), 1.08-1.15 (m, 4H), 1.26-1.39 (m, 2H), 2.38-2.43 (m, 2H), 3.63 (s, 3H), 5.08 (s, 2H), 7.08-7.11 (m, 2H), 7.24-7.38 (m, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  13.82, 22.07, 24.13, 29.96, 31.36, 50.60, 51.02, 113.15, 123.85, 126.25, 126.68, 126.74, 127.46, 127.85, 128.89, 130.40, 132.74, 135.59, 137.02, 165.06.

Synthesis of compounds 17 and 18. Syntheses of compounds 17a-c and 18a-c were carried out similarly for the synthesis of compound 9, and the spectroscopic data of 17a-c and 18a-c are as follows.

Compound **17a**: 58% (entry 4 in Table 2); yellow solid, mp 138-140 °C; IR (film) 2926, 1716, 1521, 1210 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  1.18 (t, J = 7.2 Hz, 3H), 3.51 (s, 3H), 3.79 (s, 3H), 4.17 (q, J = 7.2 Hz, 2H), 6.37-6.43 (m, 2H), 6.85-6.88 (m, 2H), 6.98-7.28 (m, 9H), 7.50 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  14.24, 55.39, 55.47, 59.37, 99.31, 104.07, 114.44, 121.74, 123.75, 126.05, 126.60, 127.16, 127.36, 129.10, 129.32, 130.28, 131.17, 131.70, 133.84, 134.92, 155.23, 160.51, 164.69; ESIMS *m/z* 428 (M<sup>+</sup>+1). Anal. Calcd for C<sub>27</sub>H<sub>25</sub>NO<sub>4</sub>: C, 75.86; H, 5.89; N, 3.28. Found: C, 75.92; H, 5.78; N, 3.03.

Compound **18a**: 52% (entry 1 in Table 2); yellow solid, mp 150-152 °C; IR (film) 3392, 2937, 1705, 1514 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  0.95 (t, J = 7.2 Hz, 3H), 3.48 (s, 3H), 3.68 (s, 3H), 3.69 (s, 3H), 3.74 (s, 3H), 4.02 (q, J = 7.2 Hz, 2H), 6.15-6.24 (m, 3H), 6.28 (d, J = 2.7 Hz, 1H), 6.68 (d, J = 8.7 Hz, 1H), 6.84-6.99 (m, 7H), 7.11-7.21 (m, 3H), 7.24-7.28 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  13.80, 55.07, 55.31, 55.51, 55.57, 59.09, 98.56, 98.68, 102.11, 103.38, 103.90, 117.94, 119.08, 122.04, 125.72, 126.23, 126.92, 127.11, 127.37, 128.88, 130.24, 130.68, 131.29, 131.96, 135.75, 140.99, 150.19, 154.62, 155.65, 160.37, 165.56; ESIMS *m*/*z* 579 (M<sup>+</sup>+1). Anal. Calcd for C<sub>35</sub>H<sub>34</sub>N<sub>2</sub>O<sub>6</sub>: C, 72.65; H, 5.92; N, 4.84. Found: C, 72.28; H, 5.68; N, 4.97.

Compound **17b**: 50%; yellow solid, mp 147-149 °C; IR (film) 2980, 1716, 1516, 1251 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  1.18 (t, J = 7.0 Hz, 3H), 3.78 (s, 3H), 4.18 (q, J = 7.0 Hz, 2H), 6.80 (d, J = 9.0 Hz, 2H), 6.87-6.89 (m, 2H), 7.04-7.09 (m, 5H), 7.18-7.25 (m, 5H), 7.60 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  14.20, 55.40, 59.49, 114.08, 114.82, 124.94, 126.22, 126.87, 127.02, 127.21, 127.70, 128.48,

130.93, 131.07 (2C), 132.49, 132.61, 134.72, 158.61, 164.56.

Compound **18b**: 14%; yellow solid, mp 113-115 °C; IR (film) 3319, 2951, 1709, 1512 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  0.98 (t, J = 7.0 Hz, 3H), 3.67 (s, 3H), 3.69 (s, 3H), 4.06 (q, J = 7.0 Hz, 2H), 6.56 (d, J = 9.0 Hz, 2H), 6.59 (d, J = 9.0 Hz, 2H), 6.68 (d, J = 9.0 Hz, 2H), 6.85-6.87 (m, 2H), 6.90 (d, J = 9.0 Hz, 2H), 6.97-7.01 (m, 3H), 7.16-7.26 (m, 6H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  13.86, 55.24, 55.48, 59.27, 101.56, 113.45, 113.88, 121.21, 122.21, 125.91, 126.51, 126.98, 127.41, 128.30, 129.41, 129.81, 131.22, 131.35, 131.36, 135.55, 137.42, 142.61, 154.92, 158.40, 166.17.

Compound **17c**: 37%; white solid, mp 139-141 °C; IR (film) 3128, 1693, 1520, 1227 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  1.19 (t, J = 7.0 Hz, 3H), 4.18 (q, J = 7.0 Hz, 2H), 6.87-6.89 (m, 2H), 7.04-7.13 (m, 5H), 7.19-7.32 (m, 8H), 7.66 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  14.21, 59.55, 115.25, 125.30, 125.84, 126.30, 126.97, 127.24, 127.33, 127.74, 128.36, 128.98, 129.08, 130.91, 131.00, 131.08, 134.62, 139.45, 164.51; LCMS *m/z* 368 (M<sup>+</sup>+1).

Compound **18c**: 11%; yellow oil; IR (film) 3333, 3060, 1705, 1498 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  0.96 (t, J = 7.0 Hz, 3H), 4.04 (q, J = 7.0 Hz, 2H), 6.68-7.28 (m, 21H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  13.80, 59.43, 103.90, 117.62, 120.90, 122.90, 126.07, 126.71, 127.06, 127.39, 127.47, 128.16, 128.33, 128.47, 128.56, 131.20, 131.23, 131.34, 135.28, 136.88, 139.55, 144.48, 165.70.

Acknowledgments. This study was financially supported by Chonnam National University, 2007. Spectroscopic data was obtained from the Korea Basic Science Institute, Gwangju branch.

#### **References and Notes**

- For the synthesis and biological activities of pyrrole derivatives, see: (a) Fan, H.; Peng, J.; Hamann, M. T.; Hu, J.-F. Chem. Rev. 2008, 108, 264-287. (b) Gupton, J. T. Top. Heterocycl. Chem. 2006, 2, 53-92. (c) Bellina, F.; Rossi, R. Tetrahedron 2006, 62, 7213-7256. (d) Knight, D. W.; Sharland, C. M. Synlett 2003, 2258-2260. (f) Magnus, N. A.; Staszak, M. A.; Udodong, U. E.; Wepsiec, J. P. Org. Proc. Res. Dev. 2006, 10, 899-904. (g) Cohnen, E.; Dewald, R. Synthesis 1987, 566-568. (h) Misra, N. C.; Panda, K.; Ila, H.; Junjappa, H. J. Org. Chem. 2007, 72, 1246-1251 and further references cited therein. (i) Khalili, B.; Jajarmi, P.; Eftekhari-Sis, B.; Hashemi, M. M. J. Org. Chem. 2008, 73, 2090-2095.
- For the synthesis and biological activities of pyrrole-containing compounds, see: (a) Thasana, N.; Worayuthakarn, R.; Kradanrat, P.; Hohn, E.; Young, L.; Ruchirawat, S. J. Org. Chem. 2007, 72, 9379-9382. (b) Su, S.; Porco, J. A. Jr. J. Am. Chem. Soc. 2007, 129, 7744-7745. (c) Dhawan, R.; Arndtsen, B. A. J. Am. Chem. Soc. 2004, 126, 468-469. (d) Pandey, P. S.; Rao, T. S. Bioorg. Med. Chem. Lett. 2004, 14, 129-131.
- For the general review on Baylis-Hillman chemistry, see: (a) Basavaiah, D.; Rao, A. J.; Satyanarayana, T. Chem. Rev. 2003, 103, 811-891. (b) Kim, J. N.; Lee, K. Y. Curr. Org. Chem. 2002, 6, 627-645. (c) Lee, K. Y.; Gowrisankar, S.; Kim, J. N. Bull. Korean Chem. Soc. 2005, 26, 1481-1490. (d) Singh, V.; Batra, S. Tetrahedron 2008, 64, 4511-4574 and further references cited therein.
- 4. For the synthesis of pyrroles from Baylis-Hillman adducts, see: (a) Declerck, V.; Ribiere, P.; Martinez, J.; Lamaty, F. J. Org.

2220 Bull. Korean Chem. Soc. 2008, Vol. 29, No. 11

Jeong Mi Kim et al.

*Chem.* **2004**, *69*, 8372-8381. (b) Shi, M.; Xu, Y.-M. *Eur. J. Org. Chem.* **2002**, 696-701. (c) Roy, A. K.; Pathak, R.; Yadav, G. P.; Maulik, P. R.; Batra, S. *Synthesis* **2006**, 1021-1027. (d) Singh, V.; Kanojiya, S.; Batra, S. *Tetrahedron* **2006**, *62*, 10100-10110.

- (a) Lee, H. S.; Kim, J. M.; Kim, J. N. *Tetrahedron Lett.* 2007, *48*, 4119-4122.
   (b) Kim, S. J.; Kim, H. S.; Kim, T. H.; Kim, J. N. *Bull. Korean Chem. Soc.* 2007, *28*, 1605-1608.
- For some leading references on the Barbier reaction, see: (a) Kabalka, G. W.; Venkataiah, B.; Chen, C. *Tetrahedron Lett.* 2006, 47, 4187-4189. (b) Lee, A. S.-Y.; Chang, Y.-T.; Wang, S.-H.; Chu, S.-F. *Tetrahedron Lett.* 2002, 43, 8489-8492. (c) Lee, K. Y.; Park, D. Y.; Kim, J. N. *Bull. Korean Chem. Soc.* 2006, 27, 1489-1492. (d) Isaac, M. B.; Paquette, L. A. *J. Org. Chem.* 1997, 62, 5333-5338. (e) Paquette, L. A.; Mendez-Andino, J. *Tetrahedron Lett.* 1999, 40, 4301-4304.
- 7. Although compound **8** was unstable, but we isolated this compound by rapid column chromatographic purification process and confirmed the structure as follows: 35%; yellow oil; IR (film) 3029, 1731, 1496, 1175 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  1.09 (t, *J* = 7.2 Hz, 3H), 3.48 (t, *J* = 10.8 Hz, 1H), 3.60 (dd, *J* = 10.8 Hz

and 6.0 Hz, 1H), 3.84 (d, J = 14.7 Hz, 1H), 4.01 (d, J = 14.7 Hz, 1H), 3.99-4.19 (m, 3H), 6.92-6.99 (m, 3H), 7.03-7.08 (m, 2H), 7.21-7.39 (m, 10H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$  14.02, 50.48, 54.76 (2C), 60.61, 110.44, 124.60, 126.99, 127.20, 127.71, 127.76, 128.38, 128.41, 128.71, 129.57, 133.36, 136.12, 138.77, 150.19, 174.39.

- Aerobic oxidation of dihydropyrroles to pyrrole, see: Shim, Y. K.; Youn, J. I.; Chun, J. S.; Park, T. H.; Kim, M. H.; Kim, W. J. Synthesis 1990, 753-754.
- For the Michael addition of enamine intermediate, see: Panunzio, M.; Lentini, M. A.; Campana, E.; Martelli, G.; Tamanini, E.; Vicennati, P. Synth. Commun. 2004, 34, 345-359.
- Some examples on the synthesis of pyrrole derivatives involving enamine intermediate, see: (a) Demir, A. S.; Aybey, A.; Kayalar, M. *ARKIVOC* 2005 (xv) 105-116. (b) Demir, A. S.; Emrullahoglu, M. *Tetrahedron* 2005, *61*, 10482-10489. (c) Prior, A. M.; Robinson, R. S. *Tetrahedron Lett.* 2008, *49*, 411-414.
- (a) Witkop, B. J. Am. Chem. Soc. 1956, 78, 2873-2882. (b) Malhotra, S. K.; Hostynek, J. J.; Lundin, A. F. J. Am. Chem. Soc. 1968, 90, 6565-6566.